



**Perceptronix**  
Early diagnosis, better outcomes™

## **PRESS RELEASE**

*For immediate release*

### **PERCEPTRONIX SIGNS CONTRIBUTION AGREEMENT WITH NATIONAL RESEARCH COUNCIL CANADA**

**VANCOUVER, CANADA (August, 14 2006)** – Perceptronix Medical Inc. (“Perceptronix”) announced today that the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) has agreed to provide a financial contribution in support of the development of its ClearVu™ Elite advanced fluorescence bronchoscopy system.

ClearVu™ Elite, which is presently the subject of an international clinical study in Coventry, UK; St. Petersburg, Russia; Ljubljana, Slovenia; and Vancouver, Canada, is a fluorescence bronchoscopy system that adds practical spectroscopy measurements to fluorescence and reflectance imaging.

The study provides data to verify if spectroscopy measurements combined with fluorescence imaging can help bronchoscopists to distinguish benign conditions that mimic cancer from real cancerous lesions, as indicated by the pre-clinical data. Although fluorescence bronchoscopy has been proven to significantly detect more lesions of early lung cancer, this comes at the cost of taking significantly more biopsies of what ultimately prove to be benign sites. ClearVu™ Elite could reduce both patient risk and medical costs if the number of biopsies taken could be reduced with minimal loss of sensitivity for detecting lung cancer.

“The project will involve analysis of data collected internationally with regards to the various engineering, scientific and medical issues, making the project both complex and ambitious.” said Dr. Bojana Turic, Perceptronix Vice-President & Chief Operating Officer.

NRC-IRAP works with Canadian small- and medium-sized enterprises to provide a range of both technical and business oriented advisory services along with potential financial support to these growth-oriented companies.

“Perceptronix has an ambitious vision for a start-up company,” said Dr. David Garner, Perceptronix Vice-President & Chief Science Officer. “Our company is encouraged by this contribution agreement and is energetically moving forward on the ClearVu™ Elite endoscopy system.”

#### **Fluorescence Bronchoscopy and Lung Cancer**

Fluorescence bronchoscopy has dramatically improved physicians’ ability to locate early stage lung cancer for biopsy and treatment. Early detection is the key to improving survival for lung cancer patients. Lung cancer remains the leading cause of cancer death for both men and women in much of the developed world. Of the more than 21,000 Canadians diagnosed with lung cancer every year, fewer than 15 per cent will survive for five years. Worldwide there are approximately 1.25 million lung cancer deaths per year.

#### **Perceptronix Suite of Technologies**

The ClearVu™ Elite is one component of a comprehensive suite of cancer detection technologies Perceptronix intends to offer. The others are:



- The ClearSign™ Sputum Test. This test is used for early lung cancer detection. It received CE Mark registration in Q2, 2006 and a license application is currently under review by Health Canada;
- The ClearCyte™ Test. This test is used to measure “gross genomic aberrations” (DNA Ploidy) to assist physicians with clinical diagnosis and prognosis of cancer. This test has a Health Canada license and CE Mark;
- The Clear2C™ Quantitative DNA Staining Kit which is used with ClearCyte™ and has a Health Canada license, CE Mark and US Food & Drug Administration Medical Device Listing;
- ClearVu™ simultaneous fluorescence/white light endoscopy system is an instrument designed to assist with cancer localization. This product is currently in the development stage.
- ClearPath™, an instrument designed to assist in the definitive diagnosis of biopsy sections. This product is currently in the development stage.

The Perceptronix **Clinical Quantitative Cytology Laboratory** in Vancouver, Canada, currently offers the **ClearCyte™** Test to assist clinicians in the diagnosis and prognosis of cancer and intends to offer the **ClearSign™** Sputum Test once the Health Canada license is received.

**About Perceptronix Medical Inc. ([www.perceptronix.com](http://www.perceptronix.com))**

Perceptronix is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency ([www.bccancer.bc.ca](http://www.bccancer.bc.ca)), a world-leader in cancer care and research and a pioneer in early cancer detection programs.

*This press release is not, and under no circumstances is to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc.*

**Contact:**

Susan Grose

Corporate Secretary  
Perceptronix Medical Inc.  
Ste. 400, 555 West 8<sup>th</sup> Avenue  
Vancouver, Canada V5Z 1C6  
Phone: (604) 707 – 9037  
[info@perceptronix.com](mailto:info@perceptronix.com)